Postoperative Facial Nerve Dysfunction
Conditions
Keywords
Facial Nerve Dysfunction, Temporomandibular Joint Surgery, Photobiomodulation Therapy, Low-Level Laser Therapy, Facial Nerve Recovery
Brief summary
This randomized clinical trial compared two photobiomodulation systems for the management of postoperative facial nerve dysfunction following temporomandibular joint surgery. Patients who developed clinically detectable facial nerve dysfunction after open temporomandibular joint surgery were randomly assigned to receive photobiomodulation using either the GRR Laser system or the SiroLaser Advance Plus system. Photobiomodulation was initiated on the first postoperative day and consisted of 15 treatment sessions. Facial nerve recovery was evaluated using the House-Brackmann Grading System, the Sunnybrook Facial Grading System, and the Facial Clinimetric Evaluation (FaCE) Scale during a 60-day follow-up period.
Detailed description
This prospective, randomized, parallel-group clinical trial was conducted in patients who developed postoperative facial nerve dysfunction following open temporomandibular joint surgery. Eligible participants were randomly allocated in a 1:1 ratio to one of two active photobiomodulation treatment groups using a computer-generated block randomization sequence. Participants assigned to the GRR Laser group received extraoral transcutaneous photobiomodulation using a dual-wavelength 650-nm and 904-nm laser/LED system. Participants assigned to the SiroLaser Advance Plus group received extraoral transcutaneous photobiomodulation using a 660-nm continuous-wave diode laser. In both groups, irradiation was applied along the anatomical projection of the clinically affected facial nerve branches on the operated side. Photobiomodulation treatment was initiated on the first postoperative day. Treatment was administered daily during the first five postoperative days and every other day thereafter, for a total of 15 treatment sessions. Each treatment session lasted approximately 10 minutes. Facial nerve function was evaluated on postoperative days 5, 7, 10, 30, and 60. Clinical assessments included the House-Brackmann Grading System and the Sunnybrook Facial Grading System. Patient-reported functional status and quality of life were assessed using the Facial Clinimetric Evaluation (FaCE) Scale. The first standardized outcome assessment was performed on postoperative day 5; therefore, this assessment represented the first standardized postoperative evaluation rather than a pretreatment baseline.
Interventions
DEVICEGRR Laser Photobiomodulation System
Extraoral transcutaneous photobiomodulation was delivered using the GRR Laser system, a dual-wavelength 650-nm and 904-nm laser/LED system. Treatment was applied along the anatomical projection of the clinically affected facial nerve branches. Treatment began on the first postoperative day and consisted of 15 sessions, administered daily during the first 5 postoperative days and every other day thereafter. Each session lasted approximately 10 minutes.
DEVICESiroLaser Advance Plus
Extraoral transcutaneous photobiomodulation was delivered using the SiroLaser Advance Plus system in SoftLase mode. Irradiation was provided using a 660-nm continuous-wave diode laser with an output power of 25 mW through an 8-mm fiber-optic tip. Treatment was applied along the anatomical projection of the clinically affected facial nerve branches. Treatment began on the first postoperative day and consisted of 15 sessions using the same treatment schedule as the GRR Laser group.
Sponsors
Ankara University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Participants were randomized in a 1:1 ratio to one of two parallel active photobiomodulation treatment groups.
Eligibility
Sex/Gender
ALL
Healthy volunteers
No
Inclusion criteria
* Patients who underwent open temporomandibular joint surgery. * Presence of clinically confirmed postoperative facial nerve dysfunction. * Willingness to comply with the follow-up protocol and attend scheduled follow-up visits. * Provision of written informed consent.
Exclusion criteria
* Pre-existing facial nerve paralysis or facial nerve dysfunction before surgery. * History of central neurological disease. * Previous surgery involving the facial nerve. * History of head and neck malignancy and/or chemotherapy or radiotherapy that could potentially affect facial nerve function.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Sunnybrook Facial Grading System Score | From postoperative day 5 to postoperative day 60 | The Sunnybrook Facial Grading System was used to assess facial nerve function based on resting symmetry, voluntary facial movement, and synkinesis. The composite score ranges from 0 to 100, with higher scores indicating better facial nerve function. The change score was calculated as the postoperative day 60 score minus the postoperative day 5 score. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| House-Brackmann Grading System | Postoperative days 5, 7, 10, 30, and 60 | Facial nerve function was graded using the House-Brackmann Grading System, which classifies facial nerve function from Grade I (normal function) to Grade VI (complete paralysis), with higher grades indicating greater dysfunction. |
| Facial Clinimetric Evaluation (FaCE) Scale | Postoperative days 5, 7, 10, 30, and 60 | The FaCE Scale is a 15-item patient-reported measure assessing facial movement, facial comfort, oral function, eye comfort, lacrimal control, and social function. Total scores are transformed to a 0-100 scale, with higher scores indicating better facial function and quality of life. |
Countries
Turkey (Türkiye)
Contacts
PRINCIPAL_INVESTIGATORMehmet Emre Yurttutan, DDS, PhD
Ankara University
Outcome results
None listed